Sana Biotechnology SANA Change in fair value of contingent consideration
Change in fair value of contingent consideration at other companies
Other financials
Where this comes from
Reported directly by Sana Biotechnology in its filing.
Tagged under the XBRL concept us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1.
The official record: Sana Biotechnology’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Sana Biotechnology's change in fair value of contingent consideration.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Sana Biotechnology's change in fair value of contingent consideration?
- Sana Biotechnology (SANA) reported change in fair value of contingent consideration of $10.75M in Q1 2026.
- How has Sana Biotechnology's change in fair value of contingent consideration changed year-over-year?
- Sana Biotechnology's change in fair value of contingent consideration increased by 476.4% year-over-year, from $1.86M to $10.75M.
- What does change in fair value of contingent consideration mean?
- This represents the non-cash adjustment to the estimated fair value of liabilities related to future payments contingent upon the achievement of specific milestones or performance targets from past acquisitions. Changes in this value reflect management's updated assessment of the probability and timing of meeting these contractual obligations. It is a key indicator of potential future cash outflows tied to strategic business combinations.